Watchlist Price Alert

Verastem Inc. (VSTM)

NASDAQ: VSTM · Real-Time Price · USD

5.62

0.02 (0.36%)

At close: Jun 16, 2025, 3:59 PM

5.60

-0.36%

After-hours: Jun 16, 2025, 07:58 PM EDT

0.36% (1D)

Bid	5.6
Market Cap	308.81M
Revenue (ttm)	24K
Net Income (ttm)	-148.88M
EPS (ttm)	-3.36
PE Ratio (ttm)	-1.67
Forward PE	-3.11
Analyst	Buy

Ask	5.69
Volume	812,823
Avg. Volume (20D)	1,603,565
Open	5.63
Previous Close	5.60
Day's Range	5.48 - 5.70
52-Week Range	2.10 - 9.10
Beta	0.85

About VSTM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol VSTM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for VSTM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

-19.95%

Verastem shares are trading lower. The company pro... Unlock content with Pro Subscription

3 weeks ago

-1.71%

Verastem Oncology shares are trading higher after the company announced phase 2 dose level 1 shows 83% overall response rate in frontline metastatic pancreatic ductal adenocarcinoma.

News

2 weeks ago · businesswire.com

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive ...

2 weeks ago · zacks.com

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a co...

1 month ago · businesswire.com

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

1 month ago · businesswire.com

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)---- $VSTM #FDA--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today anno...

1 month ago · reuters.com

U.S. FDA approves Verastem's cancer therapy

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer who have received prior treatment, the regulator said on Thursday.